Refine By

Stock Exchange

Analyst

Sector

Type of Publication

alnylam

1 - 5 of 5
Sort by: popularity | newest
Page  of 1
Trillium Therapeutics

Edison healthcare quarterly: Immunotherapy takes centre stage

Sector Commentary: | Pharmaceutical & healthcare | 31 Jul 2013

-

Merrimack Pharmaceuticals

Edison healthcare quarterly: German (drug) reformation

Sector Commentary: | Pharmaceutical & healthcare | 10 Apr 2013

-

Tekmira

Litigation pays off

QuickView | Pharmaceutical & healthcare | 16 Nov 2012

Canada's Tekmira is well positioned to advance its internal RNAi drug candidates and enter new partnerships following its eve-of-trial litigation settlement and licensing deal with US RNAi giant Alnylam. The deal consolidates Tekmira's ownership of lipid nanoparticle (LNP) delivery IP and boosts its cash runway to 2015. Tekmira's shares have surged 30% in the last 10 days in anticipation of and following the settlement.

Cytos Biotechnology

Edison healthcare quarterly: Crisis? What crisis?

Sector Commentary: | Pharmaceutical & healthcare | 30 Aug 2012

-

Alnylam Pharmaceuticals

On the fast track

QuickView | Pharmaceutical & healthcare | 10 Feb 2012

Alnylam plans to speed the clinical development of two leads that it says offer the greatest commercial opportunity o ALN-TTR for transthyretin-mediated amyloidosis and ALN-APC for haemophilia. While it still aims to have five rare disease therapeutics in late trials by 2015, it is seeking further development partners for three of these: ALN-PCS for severe hypercholesterolemia (Phase I), ALN-HPN for refractory anaemia and ALN-TMP for haemoglobinopathies (both preclinical). Alnylam finished 2011 with a healthy $261m in cash, but is cutting 33% of its staff to save $20m a year and help transform it from a platform- to a product-based company; there should also be a slight reduction in future R&D spending.